Paul F. Bray

Paul F. Bray, MD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Hematology & Hematologic Malignancies

Academic Office Information

paul.bray@hsc.utah.edu

Board Certification

  • American Board of Internal Medicine
  • Federal Licensing Examination
  • American Board of Internal Medicine (Sub: Hematology)
  • National Board of Medical Examiners
  • American Board of Internal Medicine (Sub: Medical Oncology)

Throughout his full academic career, Dr. Bray has cared for patients with blood diseases. His clinical interests include: 1) Benign and non-malignant hematology, 2) Disorders of platelet number and function, 3) Bleeding disorders, and 4) Thrombotic disorders.

Dr. Bray’s laboratory performs basic and translational research on 1) the role of platelets in inherited and acquired disorders of hemostasis, thrombosis and cardiovascular disease, 2) racial differences in platelet function, myocardial infarction and stroke, 3) genomic and transcriptomic approaches to identification of novel genes and gene variants involved in platelet reactivity and pharmacogenetics, and 4) the role of platelet and megakaryocyte microRNAs (and other non-coding RNAs) on platelet gene expression and physiology.

He has published more than 180 peer-reviewed papers, book chapters and invited reviews

Research Statement

Dr. Bray has over 30 years of experience in the molecular genetics and cell biology of platelets. In particular, he has a long research interest in arterial thrombosis and has expertise in platelet molecular biology, genetics, RNA expression, microRNAs, genomics and functional characterization of genetic variants, having discovered the first inherited platelet risk factor for myocardial infarction. He has expertise in platelet physiology and designing assays to assess platelet reactivity. He designed and conducted research studies that recruited cohorts to identify genes, SNPs and mRNAs associated with human platelet activation. He was the first to demonstrate viral-vector mediated gene expression in cultured megakaryocytes. His laboratory has used human platelet mRNA expression profiling to discover novel platelet mRNAs and microRNAs associated with platelet aggregation and differentially expressed between different hematopoietic cells. Dr. Bray has extensive experience with candidate SNP and pharmacogenetics association studies in large cohorts, having collaborated and published with the investigators in TIMI, Framingham, John’s Hopkins’ GeneSTAR, the Women’s Health Initiative, and HERS. The PRAX1 study was designed and executed by Dr. Bray. This study resulted in the identification of racial differences in platelet function, and he demonstrated several novel molecular mechanisms to explain these racial differences. He and his collaborators at Baylor College of Medicine generated and maintain a public, user-friendly, interactive web tool (www.plateletomics.com) to query human platelet mRNA, microRNA and protein expression, mouse platelet mRNA, and human RNA-demographic and RNA-functional associations, facilitating discovery of mechanisms of platelet-megakaryocyte gene expression.

Dr. Bray has had 30 years of continuous funding from the National Institutes of Health (NIH) and currently is PI on three NIH R01 grants. He has published more than 160 peer-reviewed papers, book chapters and invited reviews.

Education History

Undergraduate University of San Francisco
 BS
Professional Medical University of Utah School of Medicine
 MD
Internship Baylor College of Medicine
 Intern
Residency Baylor College of Medicine
 Resident
Fellowship University of California, San Francisco
 Fellow
Postdoctoral Fellowship University of California, San Francisco
 Postdoctoral Fellow

Selected Publications

Journal Article

  1. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC (2002). Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J, 143(1), 76-82.
  2. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moye LA, Pfeffer MA, Sacks FM, Braunwald E (2001). The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol, 88(4), 347-52.
  3. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, Bray PF, Becker LC (2006). Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol, 98(6), 774-9.
  4. Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL (2008). Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol, 101(11), 1599-1605.
  5. McTiernan A, Wactawski-Wende J, Wu L, Rodabough RJ, Watts NB, Tylavsky F, Freeman R, Hendrix S, Jackson R (2009). Low-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr, 89(6), 1864-76.
  6. Li L, Bray PF (1993). Homologous recombination among three intragene Alu sequences causes an inversion-deletion resulting in the hereditary bleeding disorder Glanzmann thrombasthenia. Am J Hum Genet, 53(1), 140-9.
  7. Faraday N, Martinez EA, Scharpf RB, Kasch-Semenza L, Dorman T, Pronovost PJ, Perler B, Gerstenblith G, Bray PF, Fleisher L (2004). Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology, 101(6), 1291-7.
  8. Goldschmidt-Clermont PJ, Coleman LD, Pham YM, Cooke GE, Shear WS, Weiss EJ, Kral BG, Moy TF, Yook RM, Blumenthal RS, Becker DM, Becker LC, Bray P (1999). Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease. Archives of pathology & laboratory medicine, 123(12), 1223-9.
  9. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont P (2001). The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Archives of pathology & laboratory medicine, 125(1), 112-5.
  10. Margolis KL, Manson JE, Greenland P, Rodabough RJ, Bray PF, Safford M, Grimm RH Jr, Howard BV, Assaf AR, Prentice (2005). Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Archives of internal medicine, 165(5), 500-8.
  11. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal F (2006). Venous thrombosis and conjugated equine estrogen in women without a uterus. Archives of internal medicine, 166(7), 772-80.
  12. Rossouw JE, Cushman M, Greenland P, Lloyd-Jones DM, Bray P, Kooperberg C, Pettinger M, Robinson J, Hendrix S, Hsia (2008). Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Archives of internal medicine, 168(20), 2245-53.
  13. Payne KE, Bray PF, Grant PJ, Carter A (2008). Beta3 integrin haplotype influences gene regulation and plasma von Willebrand factor activity. Atherosclerosis, 198(2), 280-6.
  14. Bray PF, Shuman M (1990). Identification of an abnormal gene for the GPIIIa subunit of the platelet fibrinogen receptor resulting in Glanzmann's thrombasthenia. Blood, 75(4), 881-8.
  15. Rosa JP, Bray PF, Gayet O, Johnston GI, Cook RG, Jackson KW, Shuman MA, McEver R (1988). Cloning of glycoprotein IIIa cDNA from human erythroleukemia cells and localization of the gene to chromosome 17. Blood, 72(2), 593-600.
  16. Wilhide CC, Van Dang C, Dipersio J, Kenedy AA, Bray P (1995). Overexpression of cyclin D1 in the Dami megakaryocytic cell line causes growth arrest. Blood, 86(1), 294-304.
  17. Bray PF, Jin Y, Kickler (1994). Rapid genotyping of the five major platelet alloantigens by reverse dot-blot hybridization. Blood, 84(12), 4361-7.
  18. Villa-Garcia M, Li L, Riely G, Bray P (1994). Isolation and characterization of a TATA-less promoter for the human beta 3 integrin gene. Blood, 83(3), 668-76.
  19. Jin Y, Dietz HC, Nurden A, Bray P (1993). Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood, 82(8), 2281-8.
  20. Wilhide CC, Jin Y, Guo Q, Li L, Li SX, Rubin E, Bray P (1997). The human integrin beta3 gene is 63 kb and contains a 5'-UTR sequence regulating expression. Blood, 90(10), 3951-61.
  21. Jin Y, Wilhide CC, Dang C, Li L, Li SX, Villa-Garcia M, Bray P (1998). Human integrin beta3 gene expression: evidence for a megakaryocytic cell-specific cis-acting element. Blood, 92(8), 2777-90.
  22. Faraday N, Rade JJ, Johns DC, Khetawat G, Noga SJ, DiPersio JF, Jin Y, Nichol JL, Haug JS, Bray P (1999). Ex vivo cultured megakaryocytes express functional glycoprotein IIb-IIIa receptors and are capable of adenovirus-mediated transgene expression. Blood, 94(12), 4084-92.
  23. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, Bray P (2000). Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood, 95(7), 2289-96.
  24. Wilcox DA, Olsen JC, Ishizawa L, Bray PF, French DL, Steeber DA, Bell WR, Griffith M, White GC 2n (2000). Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood, 95(12), 3645-51.
  25. McCarty OJ, Mousa SA, Bray PF, Konstantopoulos (2000). Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood, 96(5), 1789-97.
  26. Li TT, Larrucea S, Souza S, Leal SM, Lopez JA, Rubin EM, Nieswandt B, Bray P (2004). Genetic variation responsible for mouse strain differences in integrin alpha 2 expression is associated with altered platelet responses to collagen. Blood, 103(9), 3396-402.
  27. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray P (2005). Aggregometry detects platelet hyperreactivity in healthy individuals. Blood, 106(8), 2723-9.
  28. Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington D (2007). Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood, 109(5), 1862-9.
  29. Bergmeier W, Oh-Hora M, McCarl CA, Roden RC, Bray PF, Feske (2009). R93W mutation in Orai1 causes impaired calcium influx in platelets. Blood, 113(3), 675-8.
  30. Bray P (2009). Platelet genomics beats the catch-22. Blood, 114(7), 1286-7.
  31. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, Lopez JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray P (2011). Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 117(19), 5189-97.
  32. Faraday N, Yanek LR, Yang XP, Mathias R, Herrera-Galeano JE, Suktitipat B, Qayyum R, Johnson AD, Chen MH, Tofler GH, Ruczinski I, Friedman AD, Gylfason A, Thorsteinsdottir U, Bray PF, O'Donnell CJ, Becker DM, Becker L (2011). Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood, 118(12), 3367-75.
  33. Bray P (2013). Dengue platelets meet Sir Arthur Conan Doyle. Blood, 122(20), 3400-1.
  34. Simon LM, Edelstein LC, Nagalla S, Woodley AB, Chen ES, Kong X, Ma L, Fortina P, Kunapuli S, Holinstat M, McKenzie SE, Dong JF, Shaw CA, Bray P (2014). Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood, 123(16), e37-45.
  35. Zhou Y, Abraham S, Andre P, Edelstein LC, Shaw CA, Dangelmaier CA, Tsygankov AY, Kunapuli SP, Bray PF, McKenzie S (2015). Anti-miR-148a regulates platelet FcgammaRIIA signaling and decreases thrombosis in vivo in mice. Blood, 126(26), 2871-81.
  36. Nagalla S, Bray P (2016). Personalized medicine in thrombosis: back to the future. Blood, 127(22), 2665-71.
  37. Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, López JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro (2016). A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 127(23), 2791-803.
  38. Londin ER, Hatzimichael E, Loher1 P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos (2013). Towards a reference human platelet transcriptome: evaluation of inter-individual correlations and of its relationship with a platelet proteome. Blood, 122, 2297.
  39. Bhatlekar S, Manne BK, Basak I, Edelstein LC, Tugolukova E, Stoller ML, Cody MJ, Morley SC, Nagalla S, Weyrich AS, Rowley JW, O'Connell RM, Rondina MT, Campbell RA, Bray P (2020). miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin. Blood, 136(15), 1760-1772.
  40. Campbell RA, Schwertz H, Hottz ED, Rowley JW, Manne BK, Washington AV, Hunter-Mellado R, Tolley ND, Christensen M, Eustes AS, Montenont E, Bhatlekar S, Ventrone CH, Kirkpatrick BD, Pierce KK, Whitehead SS, Diehl SA, Bray PF, Zimmerman GA, Kosaka Y, Bozza PT, Bozza FA, Weyrich AS, Rondina M (2019). Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3. Blood, 133(19), 2013-2026.
  41. Di Paola J, Bray P (2018). One over PAR or one under PAR: vive la différence. Blood, 132(19), 2007-2008.
  42. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, Mason E, McNeeley SG, Ascensao J, Chlebowski R (2008). Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer epidemiology, biomarkers & prevention, 17(10), 2609-18.
  43. Furman MI, Grigoryev D, Bray PF, Dise KR, Goldschmidt-Clermont P (1994). Platelet tyrosine kinases and fibrinogen receptor activation. Circulation research, 75(1), 172-80.
  44. Nealen ML, Vijayan KV, Bolton E, Bray P (2001). Human platelets contain a glycosylated estrogen receptor beta. Circulation research, 88(4), 438-42.
  45. Leng XH, Zhang W, Nieswandt B, Bray P (2005). Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circulation research, 97(5), 415-7.
  46. Rondina MT, Voora D, Simon LM, Schwertz H, Harper JF, Lee O, Bhatlekar SC, Li Q, Eustes AS, Montenont E, Campbell RA, Tolley ND, Kosaka Y, Weyrich AS, Bray PF, Rowley J (2020). Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet SELP Splice QTL. Circulation research, 126(4), 501-516.
  47. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith (1996). Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation, 94(9), 2083-9.
  48. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray P (2000). Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation, 101(9), 1013-8.
  49. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner (2006). Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation, 113(20), 2425-34.
  50. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, Becker D (2007). Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation, 115(19), 2490-6.
  51. Edelstein LC, Luna EJ, Gibson IB, Bray M, Jin Y, Kondkar A, Nagalla S, Hadjout-Rabi N, Smith TC, Covarrubias D, Jones SN, Ahmad F, Stolla M, Kong X, Fang Z, Bergmeier W, Shaw C, Leal SM, Bray P (2012). Human genome-wide association and mouse knockout approaches identify platelet supervillin as an inhibitor of thrombus formation under shear stress. Circulation, 125(22), 2762-71.
  52. Goldschmidt-Clermont PJ, Schulman SP, Bray PF, Chandra NC, Grigoryev D, Dise KR, Sagar M, Fox RJ, Coleman LD, Richardson C, Dorsey FC, du Mee C, Kitt MM, Ouyang P, Baughman KL, Gerstenblith (1996). Refining the treatment of women with unstable angina--a randomized, double-blind, comparative safety and efficacy evaluation of Integrelin versus aspirin in the management of unstable angina. Clinical cardiology, 19(11), 869-74.
  53. Holinstat M, Bray P (2015). Emerging innovative therapeutic approaches to protease receptor antagonism [doi: 10.1002/cpt.282.] [Epub ahead of print]. Clinical pharmacology and therapeutics,
  54. Luo XY, Bray PF, Magenis R (1989). Precise localization of the gene for platelet membrane glycoprotein IIb to 17q21.32 using structural rearrangements of chromosome 17. Cytogenetics and cell genetics, 51, 1036.
  55. Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, Bray P (2003). Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS letters, 540(1-3), 41-6.
  56. Botero JP, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W, Di Paola J, ClinGen Platelet Disorder Variant Curation Expert Panel (2020). Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica, 105(4), 888-894.
  57. Bhatlekar S, Basak I, Edelstein LC, Campbell RA, Lindsey CR, Italiano JE Jr, Weyrich AS, Rowley JW, Rondina MT, Sola-Visner M, Bray P (2019). Anti-apoptotic BCL2L2 increases megakaryocyte proplatelet formation in cultures of human cord blood. Haematologica, 104(10), 2075-2083.
  58. Call GK, Bray PF, Smoker WR, Buys SS, Hayes J (1990). Carotid thrombosis following neck irradiation. International journal of radiation oncology, biology, physics, 18(3), 635-40.
  59. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman N (2006). Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. Journal of the American College of Cardiology, 47(1), 27-33.
  60. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont P (2006). Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. Journal of the American College of Cardiology, 47(3), 541-6.
  61. Brunner RL, Cochrane B, Jackson RD, Larson J, Lewis C, Limacher M, Rosal M, Shumaker S, Wallace (2008). Calcium, vitamin D supplementation, and physical function in the Women's Health Initiative. Journal of the American Dietetic Association, 108(9), 1472-9.
  62. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray P (2003). Platelet hyperreactivity in women from families with premature atherosclerosis. Journal of the American Medical Women's Association (1972), 58(4), 272-7.
  63. Sohn RH, Chen J, Koblan KS, Bray PF, Goldschmidt-Clermont P (1995). Localization of a binding site for phosphatidylinositol 4,5-bisphosphate on human profilin. The Journal of biological chemistry, 270(36), 21114-20.
  64. Vijayan KV, Liu Y, Dong JF, Bray P (2003). Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. The Journal of biological chemistry, 278(6), 3860-7.
  65. Vijayan KV, Liu Y, Li TT, Bray P (2004). Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. The Journal of biological chemistry, 279(32), 33039-42.
  66. Vijayan KV, Liu Y, Sun W, Ito M, Bray P (2005). The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. The Journal of biological chemistry, 280(23), 21756-62.
  67. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, Zimmerman G (1999). Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. The Journal of cell biology, 144(1), 175-84.
  68. Bertagnolli ME, Locke SJ, Hensler ME, Bray PF, Beckerle M (1993). Talin distribution and phosphorylation in thrombin-activated platelets. Journal of cell science, 106 ( Pt 4), 1189-99.
  69. Jin Y, Dietz HC, Montgomery RA, Bell WR, McIntosh I, Coller B, Bray P (1996). Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. The Journal of clinical investigation, 98(8), 1745-54.
  70. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray P (2000). The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. The Journal of clinical investigation, 105(6), 793-802.
  71. Faraday N, Goldschmidt-Clermont P, Dise K, Bray P (1994). Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. The Journal of laboratory and clinical medicine, 123(5), 728-40.
  72. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday (2006). Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA, 295(12), 1420-7.
  73. Woods D, Cherwinski H, Venetsanakos E, Bhat A, Gysin S, Humbert M, Bray PF, Saylor VL, McMahon (2001). Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Molecular and cellular biology, 21(9), 3192-205.
  74. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont P (1996). A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. The New England journal of medicine, 334(17), 1090-4.
  75. Edwards CQ, Carrol M, Bray P, Cartwright G (1977). Hereditary hemochromatosis: Diagnosis in siblings and children. The New England journal of medicine, 297, 7-13.
  76. Bray PF, Luka J, Bray PF, Culp KW, Schlight J (1992). Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology, 42(9), 1798-804.
  77. Bray PF, Culp KW, McFarlin DE, Panitch HS, Torkelson RD, Schlight J (1992). Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. Neurology, 42(2), 278-82.
  78. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos (2015). Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 112(10), E1106-15.
  79. Buitrago L, Rendon A, Liang Y, Simeoni I, Negri A, Filizola M, Ouwehand WH, Coller B (2015). alphaIIbbeta3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences of the United States of America, 112(15), E1898-907.
  80. Wagner KR, Giles WH, Johnson CJ, Ou CY, Bray PF, Goldschmidt-Clermont PJ, Croft JB, Brown VK, Stern BJ, Feeser BR, Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley PD, Wityk RJ, Wozniak MA, Price TR, Kittner S (1998). Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study. Stroke, 29(3), 581-5.
  81. Faraday N, Goldschmidt-Clermont PJ, Bray P (1997). Gender differences in platelet GPIIb-IIIa activation. Thrombosis and haemostasis, 77(4), 748-54.
  82. Zhang JN, Bergeron AL, Yu Q, Sun C, McBride L, Bray PF, Dong J (2003). Duration of exposure to high fluid shear stress is critical in shear-induced platelet activation-aggregation. Thrombosis and haemostasis, 90(4), 672-8.
  83. Ball C, Vijayan KV, Nguyen T, Anthony K, Bray PF, Essex DW, Dong J (2008). Glutathione regulates integrin alpha(IIb)beta(3)-mediated cell adhesion under flow conditions. Thrombosis and haemostasis, 100(5), 857-63.
  84. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli J (2012). Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thrombosis and haemostasis, 107(2), 379-87.
  85. Dangelmaier C, Manne BK, Liverani E, Jin J, Bray P, Kunapuli S (2014). PDK1 selectively phosphorylates Thr(308) on Akt and contributes to human platelet functional responses. Thrombosis and haemostasis, 111(3), 508-17.
  86. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman N (2007). Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thrombosis research, 119(3), 355-60.
  87. Geng H, Zhang H, Zhang W, Nieswandt B, Bray PF, Leng (2008). Transdermal 17-beta estradiol replacement therapy reduces megakaryocyte GPVI expression. Thrombosis research, 123(1), 93-9.
  88. King KE, Kao KJ, Bray PF, Casella JF, Blakemore K, Callan NA, Kennedy SD, Kickler T (1996). The role of HLA antibodies in neonatal thrombocytopenia: a prospective study. Tissue antigens, 47(3), 206-11.
  89. Weiss EJ, Goldschmidt-Clermont PJ, Grigoryev D, Jin Y, Kickler TS, Bray P (1995). A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1A1 from P1A2. Tissue antigens, 46(5), 374-81.
  90. Bray P (2006). Platelet reactivity and genetics down on the pharm. Transactions of the American Clinical and Climatological Association, 117, 103-11; discussion 111-2.
  91. Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray P (1995). Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion, 35(10), 863-7.
  92. Segal JB, Kasper EK, Rohde C, Bray PF, Baldwin WM 3rd, Resar JR, Hruban RH, Kickler T (2001). Coagulation markers predicting cardiac transplant rejection. Transplantation, 72(2), 233-7.
  93. Addo JB, Bray PF, Grigoryev D, Faraday N, Goldschmidt-Clermont P (1995). Surface recruitment but not activation of integrin alpha IIb beta 3 (GPIIb-IIIa) requires a functional actin cytoskeleton. Arteriosclerosis, thrombosis, and vascular biology, 15(9), 1466-73.
  94. Irani K, Pham Y, Coleman LD, Roos C, Cooke GE, Miodovnik A, Karim N, Wilhide CC, Bray PF, Goldschmidt-Clermont P (1998). Priming of platelet alphaIIbbeta3 by oxidants is associated with tyrosine phosphorylation of beta3. Arteriosclerosis, thrombosis, and vascular biology, 18(11), 1698-706.
  95. Sajid M, Vijayan KV, Souza S, Bray P (2002). PlA polymorphism of integrin beta 3 differentially modulates cellular migration on extracellular matrix proteins. Arteriosclerosis, thrombosis, and vascular biology, 22(12), 1984-9.
  96. Leng XH, Hong SY, Larrucea S, Zhang W, Li TT, Lopez JA, Bray P (2004). Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arteriosclerosis, thrombosis, and vascular biology, 24(2), 376-81.
  97. Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, Faraday N, Becker L (2008). A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arteriosclerosis, thrombosis, and vascular biology, 28(8), 1484-90.
  98. Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, Cushman M, Bonds D, Hendrix S, Papanicolaou G, Howard T, Herrington (2011). Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arteriosclerosis, thrombosis, and vascular biology, 31(2), 464-9.
  99. Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat (2014). Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arteriosclerosis, thrombosis, and vascular biology, 34(12), 2644-50.
  100. Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray P (2013). Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nature medicine, 19(12), 1609-16.
  101. Leng X-H, Bray P (2005). Hormone therapy and platelet function. Drug discovery today, 2, 85-91.
  102. Nambi V, Kimball KT, Bray PF, Bergeron AL, Johnson SL, Morrisett JD, Chen C, Lin PH, Lumsden AB, Ballantyne CM, Dong J (2009). Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets, 20(3), 199-205.
  103. Bray PF, McKenzie SE, Edelstein LC, Nagalla S, Delgrosso K, Ertel A, Kupper J, Jing Y, Londin E, Loher P, Chen HW, Fortina P, Rigoutsos (2013). The complex transcriptional landscape of the anucleate human platelet. BMC genomics, 14, 1.
  104. Qayyum R, Becker LC, Becker DM, Faraday N, Yanek LR, Leal SM, Shaw C, Mathias R, Suktitipat B, Bray P (2015). Genome-wide association study of platelet aggregation in African Americans. BMC genetics, 16, 58.
  105. Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw M (2011). The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain medicine (Malden, Mass.), 12(5), 697-705.
  106. Chen J, Dong JF, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, Michelson AD, Bray P (2003). Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. Journal of thrombosis and haemostasis, 1(2), 355-62.
  107. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray P (2006). Platelet hyperreactivity generalizes to multiple forms of stimulation. Journal of thrombosis and haemostasis, 4(9), 2043-50.
  108. Bray PF, Mathias RA, Faraday N, Yanek LR, Fallin MD, Herrera-Galeano JE, Wilson AF, Becker LC, Becker D (2007). Heritability of platelet function in families with premature coronary artery disease. Journal of thrombosis and haemostasis, 5(8), 1617-23.
  109. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C, Bray P (2010). VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. Journal of thrombosis and haemostasis, 8(2), 369-78.
  110. Snoep JD, Gaussem P, Eikenboom JC, Emmerich J, Zwaginga JJ, Holmes CE, Vos HL, de Groot PG, Herrington DM, Bray PF, Rosendaal FR, van der Bom J (2010). The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. Journal of thrombosis and haemostasis, 8(11), 2377-84.
  111. Megy K, Downes K, Simeoni I, Bury L, Morales J, Mapeta R, Bellissimo DB, Bray PF, Goodeve AC, Gresele P, Lambert M, Reitsma P, Ouwehand WH, Freson K, Subcommittee on Genomics in Thrombosis and Hemostasis (2019). Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. Journal of thrombosis and haemostasis, 17(8), 1253-1260.
  112. Basak I, Bhatlekar S, Manne BK, Stoller M, Hugo S, Kong X, Ma L, Rondina MT, Weyrich AS, Edelstein LC, Bray P (2019). miR-15a-5p regulates expression of multiple proteins in the megakaryocyte GPVI signaling pathway. Journal of thrombosis and haemostasis, 17(3), 511-524.
  113. Whitley MJ, Henke DM, Ghazi A, Nieman M, Stoller M, Simon LM, Chen E, Vesci J, Holinstat M, McKenzie SE, Shaw CA, Edelstein LC, Bray P (2018). The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition. Journal of thrombosis and haemostasis, 16(12), 2501-2514.
  114. Yee DL, Dinu BR, Sun CW, Edwards RM, Justino H, Teruya J, Bray PF, Bomgaars (2008). Low prevalence and assay discordance of "aspirin resistance" in children. Pediatric blood & cancer, 51(1), 86-92.
  115. Londin ER, Hatzimichael E, Loher P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos (2014). The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. Biology direct, 9, 3.
  116. Stolla M, Pelisek J, von Bruhl ML, Schafer A, Barocke V, Heider P, Lorenz M, Tirniceriu A, Steinhart A, Bauersachs J, Bray PF, Massberg S, Schulz (2012). Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PloS one, 7(8), e43572.
  117. Garcia AE, Rico MC, Liverani E, DeLa Cadena RA, Bray PF, Kunapuli S (2013). Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. PloS one, 8(7), e69093.
  118. Teruel-Montoya R, Kong X, Abraham S, Ma L, Kunapuli SP, Holinstat M, Shaw CA, McKenzie SE, Edelstein LC, Bray P (2014). MicroRNA expression differences in human hematopoietic cell lineages enable regulated transgene expression. PloS one, 9(7), e102259.
  119. Rincon F, Friedman DP, Bell R, Mayer SA, Bray P (2014). Targeted temperature management after intracerebral hemorrhage (TTM-ICH): methodology of a prospective randomized clinical trial. International journal of stroke, 9(5), 646-51.
  120. Feldman AM, Force TL, Whellan DJ, Bray PF, Cheung JY, Koch W (2010). Advancing the research mission in an academic department: the creation of a center for translational medicine. Clinical and translational science, 3(4), 178-81.
  121. Hong W, Kondkar AA, Nagalla S, Bergmeier W, Jin Y, Herman JH, Bray P (2011). Transfection of human platelets with short interfering RNA. Clinical and translational science, 4(3), 180-2.
  122. Montenont E, Bhatlekar S, Jacob S, Kosaka Y, Manne BK, Lee O, Parra-Izquierdo I, Tugolukova E, Tolley ND, Rondina MT, Bray PF, Rowley J (2021). CRISPR-edited megakaryocytes for rapid screening of platelet gene functions. Blood advances, 5(9), 2362-2374.
  123. Abou-Ismail MY, Rodgers GM, Bray PF, Lim M (2021). Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Research and practice in thrombosis and haemostasis, 5(2), 356-365.
  124. Yee D, Bray P (2004). Platelet hyperreactivity: risk factors and the effects of hormones. 4, 72-8.
  125. Rodgers GM, Ward JH, Bray P (2022). 80¿years of Clinical Hematology. British journal of haematology, 198(5), 802.
  126. Bhatlekar S, Jacob S, Manne BK, Guo L, Denorme F, Tugolukova EA, Cody MJ, Kosaka Y, Rigoutsos I, Campbell RA, Rowley JW, O'Connell RM, Bray P (2021). Megakaryocyte-specific knockout of the Mir-99b/let7e/125a cluster lowers platelet count without altering platelet function. Blood cells, molecules & diseases, 92, 102624.
  127. Stoller ML, Basak I, Denorme F, Rowley JW, Alsobrooks J, Parsawar K, Nieman MT, Yost CC, Hamilton JR, Bray PF, Campbell R (2022). Neutrophil cathepsin G proteolysis of protease-activated receptor 4 generates a novel, functional tethered ligand. Blood advances, 6(7), 2303-2308.
  128. Manne BK, Campbell RA, Bhatlekar S, Ajanel A, Denorme F, Portier I, Middleton EA, Tolley ND, Kosaka Y, Montenont E, Guo L, Rowley JW, Bray PF, Jacob S, Fukanaga R, Proud C, Weyrich AS, Rondina M (2022). MAPK-interacting kinase 1 regulates platelet production, activation, and thrombosis. Blood, 140(23), 2477-2489.
  129. Bhatlekar S, Jacob S, Tugolukova E, Manne BK, Kosaka Y, Loher P, O'Connell RM, Planelles V, Rondina MT, Rigoutsos I, Bray P (2022). Interferon ¿-induced SAMHD1 regulates human cultured megakaryocyte apoptosis and proplatelet formation. Haematologica, 107(2), 558-561.
  130. Denorme F, Armstrong ND, Stoller ML, Portier I, Tugolukova EA, Tanner RM, Montenont E, Bhatlekar S, Cody M, Rustad JL, Ajanel A, Tolley ND, Murray DC, Boyle JL, Nieman MT, McKenzie SE, Yost CC, Lange LA, Cushman M, Irvin MR, Bray PF, Campbell R (2023). The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes. The Journal of clinical investigation, 133(18),
  131. Guo L, Jacob S, Manne BK, Kolawole EM, Guo S, Wang X, Murray D, Tugolukova EA, Portier I, Kosaka Y, Barba C, Rondina MT, Evavold B, Morley C, Bhatlekar S, Bray P (2023). Actin-bundling protein L-plastin promotes megakaryocyte rigidity and dampens proplatelet formation. Haematologica, 109(1), 331-336.
  132. Nersisyan S, Montenont E, Loher P, Middleton EA, Campbell R, Bray P, Rigoutsos (2023). Characterization of all small RNAs in and comparisons across cultured megakaryocytes and platelets of healthy individuals and COVID-19 patients. Journal of thrombosis and haemostasis, 21(11), 3252-3267.
  133. Lim MY, Wei G, Presson AP, Bray P, Rodgers G (2020). High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature. Blood coagulation & fibrinolysis, 31(8), 522-529.
  134. Gobbi G, Carubbi C, Tagliazucchi GM, Masselli E, Mirandola P, Pigazzani F, Crocamo A, Notarangelo MF, Suma S, Paraboschi E, Maglietta G, Nagalla S, Pozzi G, Galli D, Vaccarezza M, Fortina P, Addya S, Ertel A, Bray P, Duga S, Berzuini C, Vitale M, Ardissino (2019). Sighting acute myocardial infarction through platelet gene expression. Scientific reports, 9(1), 19574.

Review

  1. Edelstein LC, Bray P (2011). MicroRNAs in platelet production and activation. Blood, 117(20), 5289-96.
  2. Braunstein JB, Kershner DW, Bray P, Gerstenblith G, Schulman SP, Post WS, Blumenthal R (2002). Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. Chest, 121(3), 906-20.
  3. Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS, Dauerman HL, French PA, Becker R (2012). Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. Journal of the American College of Cardiology, 59(10), 891-900.
  4. Bray P (2007). Platelet hyperreactivity: predictive and intrinsic properties. Hematology/oncology clinics of North America, 21(4), 633-45, v-vi.
  5. Yee DL, Bray P (2004). Clinical and functional consequences of platelet membrane glycoprotein polymorphisms. Seminars in thrombosis and hemostasis, 30(5), 591-600.
  6. Bray P (1994). Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterization. Thrombosis and haemostasis, 72(4), 492-502.
  7. Lumsden AB, Rice TW, Chen C, Zhou W, Lin PH, Bray P, Morrisett J, Nambi V, Ballantyne (2007). Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World journal of surgery, 31(4), 695-704.
  8. Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, French PA, Smyth SS, Becker R (2010). Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arteriosclerosis, thrombosis, and vascular biology, 30(12), 2372-84.
  9. Bray P (2000). Platelet glycoprotein polymorphisms as risk factors for thrombosis. Current opinion in hematology, 7(5), 284-9.
  10. Kleiman NS, Freedman JE, Tracy PB, Furie BC, Bray PF, Rao SV, Phillips DR, Storey RF, Rusconi CP, French PA, Steinhubl SR, Becker R (2008). Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development. Platelets, 19(4), 239-51.
  11. Williams MS, Bray P (2001). Genetics of arterial prothrombotic risk states. Experimental biology and medicine (Maywood, N.J.), 226(5), 409-19.
  12. Vijayan KV, Bray P (2006). Molecular mechanisms of prothrombotic risk due to genetic variations in platelet genes: Enhanced outside-in signaling through the Pro33 variant of integrin beta3. Experimental biology and medicine (Maywood, N.J.), 231(5), 505-13.
  13. Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray P (2013). MicroRNAs in platelet production and activation. Journal of thrombosis and haemostasis, 11 Suppl 1, 340-50.
  14. Edelstein LC, Bray P (2012). Small RNAs as potential platelet therapeutics. Handbook of experimental pharmacology, (210), 435-45.

Book Chapter

  1. Afsharkarghan V, Bray P (2002). Platelet Polymorphisms. Platelets, 157-80.
  2. Afsharkarghan V, Vijayan KV, Bray P (2006). Platelet Polymorphisms. Platelets, 281-307.
  3. Bray PF, Jones CI, Soranzo N, Ouwehand W (2012). Platelet Genomics. Platelets,
  4. Bray P (1994). Glycoproteins IIb and IIIa: Insights into platelet aggregation derived from the study of Glanzmann thrombasthenia. 207-18.
  5. Nagalla S, Leal S, Bray P (2009). Pharmacogenetics of Platelet Inhibitors. 49-66.
  6. Nagalla S, Bray P (2012). Acquired Platelet Dysfunction.
  7. Edelstein LC, Nagalla S, Bray P (2014). MicroRNAs in Platelet Production and Activation. 101-16.

Conference Proceedings

  1. Bushnell CD, Hurn P, Colton C, Miller VM, del Zoppo G, Elkind MS, Stern B, Herrington D, Ford-Lynch G, Gorelick P, James A, Brown CM, Choi E, Bray P, Newby LK, Goldstein LB, Simpkins (2006). Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke, 37(9), 2387-99.

Case Report

  1. Khouzami AN, Kickler TS, Bray PF, Callan NA, Sciscione AC, Shumway JB, Blakemore K (1995). Molecular genotyping of fetal platelet antigens with uncultured amniocytes. American journal of obstetrics and gynecology, 173(4), 1202-6.
  2. Peyruchaud O, Nurden AT, Milet S, Macchi L, Pannochia A, Bray PF, Kieffer N, Bourre (1998). R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood, 92(11), 4178-87.
  3. Julapalli VR, Bray PF, Duchini (2003). Elevated factor VIII and portal vein thrombosis. Digestive diseases and sciences, 48(12), 2369-71.
  4. Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, Varga CF, Bray P (1996). Clues to the death of an Olympic champion. Lancet (London, England), 347(9018), 1833.
  5. Yu DR, Miller R, Bray P (1998). Clinical problem-solving. Through thick and thin. The New England journal of medicine, 338(23), 1684-7.

Editorial

  1. Bray P (2008). Sizing up platelet defects. Blood, 111, 3302-3303.

Letter

  1. Nagalla S, Bray P (2010). Platelet RNA chips dip into thrombocytosis. Blood, 115(1), 2-3.
  2. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont P (1998). PlA2 polymorphism and efficacy of aspirin. Lancet (London, England), 351(9111), 1253.
  3. Sbenghe MM, Besa E, Mahipal A, Dulau Florea A, Bray P, Caro (2012). HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease. The oncologist, 17(1), 145-6; author reply 147-8.
  4. Vijayan KV, Liu Y, Souza S, Thiagarajan P, Bray P (2006). Fibrinogen and prothrombin binding is enhanced to the Pro33 isoform of purified integrin alphaIIbbeta3. Journal of thrombosis and haemostasis, 4(4), 905-6.
  5. Sarabia SF, Raya JL, Hoogeveen RC, Bray P (2008). Human platelets differentially concentrate estradiol, estrone and testosterone. Journal of thrombosis and haemostasis, 6(4), 703-5.

Other

  1. Bray P (1998). Coagulation Lab Handbook for Pathology and Medicine residents on the pathophysiology and interpretation of clinical coagulation testing. 1-57.
  2. Bray P (2000). Platelet risk factors for arterial thrombosis. 17, 76-85.

Video/Film/CD/Web/Podcast

  1. Drelich DA, Bray P (2015). The Traditional Role of Platelets in Hemostasis, The Non-Thrombotic Role of Platelets in Health and Disease [DOI: 10.5772/60595].